HSCT, Moscow Videos
Videos by HSCT in Moscow. AHSCT RUSSIA Treatment of Multiple Sclerosis and other Autoimmune Diseases
Stop the progression of Multiple Sclerosis
to enable soundOther HSCT videos
AHSCT RUSSIA - Treatment against Autoimmune Diseases
Record date: 21.09.2021
Video content:
SYSTEMIC AUTOIMMUNE DISEASE - MULTIPLE SCLEROSIS
Prevent further decrease in the quality of your life
- It is a chronic inflammatory disorder of the central nervous system, caused by autoimmune reactivity of T-cells towards components of neural cells.
- The disease progresses slowly and, at the end, the patient is essentially confined to a wheelchair.
Leave a constant need for expensive and ineffective therapy.
- Modified Therapy helps to limit acute manifestations of the disease, but it cannot stop its progression and, in most cases, it does not provide a stable long-term effect.
- MS progression inevitably leads to impairment of the patient's ability to move, sensitive disturbances and cognitive impairment.
NON-EFFECTIVE TREATMENT:
Decreasing the rate of inflammation
Decreasing the number/size of lesions in CNS
Decreasing the number of relapses per year
And other surrogate goals of modified therapy
EFFECTIVE TREATMENT OF SYSTEMIC AUTOIMMUNE DISEASE - MULTIPLE SCLEROSIS
Stop progression for years
Prevent irreversible CNS damage and critical disability
Improve significantly neurological deficit for years
HSCT for MS is based on the rationale of using chemotherapy for ablation of an aberrant, “self-reactive” immune system and regeneration of a new self-tolerant immune system from HSCT.
HSCT is a new and promising treatment strategy in MS (> 1500 HSCT all over the world), but TRM rate - 3 – 8% for myeloablative protocols.
The use of less intensive conditioning regimens is supported by the suggestion that HSCT is not only an immunosuppressive therapy, but also could have an immunomodulatory component and low-intensity lymphoablative regimens can be associated with similar outcome results, but presented less toxicity when compared with myeloablative regimens.
The rationale of using HSCT in MS is to find the best balance between toxicity and safety and to improve long-term outcome of treatment.
THEORY OF TREATMENT I